ArticleJournal of the American Heart Association2025
Evaluation and Comparison of the PREVENT and Pooled Cohort Equations for 10-Year Atherosclerotic Cardiovascular Risk Prediction.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.Diabetes, obesity & metabolism · 2025 · on this mapTrial
- Evaluating algorithmic fairness in the performance of the AHA PREVENT equations versus pooled cohort equations among single-race and multiracial populations.American journal of preventive cardiology · 2026Article
- The PREVENT Risk Equations and Cardiovascular Prevention in East Asia.Journal of atherosclerosis and thrombosis · 2026Review
- Beyond LDL-C: Modern Lipid Management for ASCVD Prevention in Primary Care.Cardiology and therapy · 2026Review
- Comparative evaluation of the predicting risk of cardiovascular disease events versus pooled cohort equations risk scores for statin eligibility in an Iranian population.American journal of preventive cardiology · 2026Article
- Artificial intelligence-based quantification of breast arterial calcifications to predict cardiovascular morbidity and mortality.European heart journal · 2026Article
- Epidemiology of cardiovascular-kidney-metabolic syndrome.Nature reviews. Nephrology · 2026Review
- Validation and Recalibration of PCE, China-PAR, and PREVENT Models for Estimating ASCVD Risk in China.JACC. Asia · 2026Article
- AI-Quantified Breast Arterial Calcification Can Predict Heart Disease Risk From Mammograms.Journal of medical Internet research · 2026Article
- From Metabolic Syndrome to Cardiovascular-Kidney-Metabolic Syndrome (CKM): A Clinical and Pathophysiological Continuum.Biomedicines · 2026Review
- REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- External validation of the PREVENT risk score: performance and clinical utility in an Iranian population.Scientific reports · 2026Article
- PREVENT Equation Performance in Asian and Native Hawaiian and Other Pacific Islander Groups.JAMA network open · 2026Article
- Statin Eligibility Disparities with Transition from the Pooled Cohort Equations to the AHA PREVENT.medRxiv : the preprint server for health sciences · 2026Article
- Unraveling the genetic blueprint of coronary artery disease: The role of polygenic risk scores in risk prediction.American heart journal plus : cardiology research and practice · 2026Article
- Cardiovascular risk stratification without recalibration: A comparative study of the PREVENT and WHO risk scores in a multiethnic Brazilian cohort.American journal of preventive cardiology · 2026Article
- The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.American journal of preventive cardiology · 2025Review
- Predicting Risk of Cardiovascular Disease Events (PREVENT) score accuracy among people with HIV in the multicenter CNICS cohort.AIDS (London, England) · 2025Article
- Hypertension Editors' View of the 2025 Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults.Hypertension (Dallas, Tex. : 1979) · 2025Article
- Cardiovascular Risk Prediction in Older Adults.Current atherosclerosis reports · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWe compared the atherosclerotic cardiovascular disease (ASCVD) risk prediction performance of the American Heart Association's Predicting Risk of Cardiovascular Disease Events (PREVENT) Base and PREVENT Full equations (includes urine albumin/creatinine ratio, glycated hemoglobin, and social deprivation index) with the pooled cohort equations (PCEs).
methodsWe included adults, aged 40 to 75 years, with no history of ASCVD, diabetes, or statin use in 2009 from Kaiser Permanente Southern California and followed up through 2019. ASCVD was defined as myocardial infarction, fatal coronary heart disease, and fatal and nonfatal ischemic stroke. We compared model discrimination (Harrell C), mean calibration (estimated as the ratio of predicted/observed event rates), and calibration curve among the overall population and stratified by sex and race and ethnicity.
resultsOf the 559 241 adults (mean age, 54 years; 11% Asian, 11% non-Hispanic Black, and 32% Hispanic), 10 695 developed an ASCVD event (median follow-up, 10 years). Harrell C was 0.741 (95% CI, 0.736-0.745) for PREVENT Base, 0.743 (95% CI, 0.738-0.748) for PREVENT Full, and 0.741 (95% CI, 0.736-0.746) for the PCEs. Compared with the PCEs, both PREVENT equations improved Harrell C in men but not women, and in non-Hispanic Black adults but not in other races and ethnicities. Both PREVENT equations were well calibrated (mean calibration, 0.85-1.36; calibration slope, 0.69-1.27), whereas the PCEs overestimated 10-year ASCVD risk (mean calibration, 1.80-2.18; calibration slope, 0.32-0.45).
conclusionsCompared with the PCEs, PREVENT Base and Full equations better predict absolute 10-year ASCVD risk across sex and racial and ethnic groups in a contemporary US adult population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.